CSL (OTCMKTS:CSLLY) Upgraded at Royal Bank Of Canada

Royal Bank Of Canada upgraded shares of CSL (OTCMKTS:CSLLY) from a hold rating to a moderate buy rating in a research note published on Monday morning,Zacks.com reports.

Several other research analysts have also recently weighed in on CSLLY. Canaccord Genuity Group upgraded CSL from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 28th. Zacks Research raised shares of CSL from a “strong sell” rating to a “hold” rating in a research report on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Buy”.

CSL Trading Up 1.5%

CSL stock opened at $60.21 on Monday. The company has a quick ratio of 1.12, a current ratio of 2.46 and a debt-to-equity ratio of 0.50. CSL has a 12 month low of $54.10 and a 12 month high of $89.71. The stock’s 50 day moving average is $58.96 and its 200-day moving average is $67.87.

About CSL

CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.

The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.